Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Researchers explore connection between popular pain relievers, bladder cancer

08.11.2012
Duration of ibuprofen use may be related to a reduced risk, especially in those with certain genetic marker

Dartmouth researchers have found that duration of ibuprofen use was associated with a reduced risk of bladder cancer in patients in northern New England, which has a high mortality rate of this disease.

In a 2012 collaborative project with the National Cancer Institute, Margaret Karagas, PhD, co-director, Cancer Epidemiology & Chemoprevention program at Norris Cotton Cancer Center, and Professor of Community and Family Medicine at the Geisel School of Medicine at Dartmouth, and Richard Waddell, D.Sc, Research Assistant Professor of Medicine at the Geisel School of Medicine, looked for connections between ibuprofen use and bladder cancer.

Bladder cancer and ibuprofen use

Karagas did an earlier study on the relationship between bladder cancer and nonsteroidal anti-inflammatory drugs (NSAIDs) usage in New Hampshire. The new study included patients in Vermont and Maine. Researchers enrolled 1,171 participants newly diagnosed with bladder cancer and 1,418 participants who did not have bladder cancer. Karagas also added a genetic component looking at thirty-nine genes related to NSAID metabolism and studied a new class of NSAIDs known as selective cyclooxygenase (COX-2) inhibitors, such as celecoxib (Celebrex). Their results were published in the International Journal of Cancer (June 2012).

Those with specific genetic traits appear to have reduced risk

The findings in the recent study suggest that "regular use of nonaspirin nonselective NSAIDs, particularly ibuprofen, may reduce bladder cancer risk, especially among regular users for 10 years or more." However, the study also notes that observed reduction in risk was specific to individuals carrying a specific allele (or variant of a gene) related to NSAID metabolism.

Findings suggest further study needed for newer prescription pain reliever

For Karagas one of the novel findings was a trend of an increased risk of bladder cancer for those using selective COX-2 inhibitors, especially celocoxib (Celebrex). Karagas warns against leaping to any conclusions, noting, "further investigation is needed."

Karagas also stresses that this study "does not make any recommendations. It does not, in any way, suggest that patients begin taking ibuprofen as a prophylactic measure against bladder cancer, nor should patients go off any medicine prescribed by their doctor."

This research study was funded by the National Institutes of Health Grant number: N02-CP-01037

About Norris Cotton Cancer Center at Dartmouth-Hitchcock

Norris Cotton Cancer Center combines advanced cancer research at Dartmouth College and the Geisel School of Medicine at Dartmouth with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu

Donna Dubuc | EurekAlert!
Further information:
http://www.hitchcock.org
http://cancer.dartmouth.edu

More articles from Health and Medicine:

nachricht New optimal screening threshold for gestational diabetes in twin pregnancies
31.10.2014 | Elsevier Health Sciences

nachricht Unlocking the secrets of pulmonary hypertension
31.10.2014 | University of Alberta Faculty of Medicine & Dentistry

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Einladung zum Industriearbeitskreis

31.10.2014 | Veranstaltungen

Sehen ohne Brille: Modernste Laser-Verfahren und Kunstlinsen

31.10.2014 | Veranstaltungen

8. Deutscher Schulverpflegungskongress am 14. November in Vechta

31.10.2014 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Move!-Kopfstütze für Menschen mit Muskelschwäche gewinnt zweiten Platz beim Kölner Design Preis

31.10.2014 | Förderungen Preise

IBT® Connect von time4you verschafft Flexibilität bei der Integration von Lerninhalten

31.10.2014 | Unternehmensmeldung

Siemens erhält Aufträge über zwei neue Windprojekte in Kanada

31.10.2014 | Unternehmensmeldung